| Therapeutic | Dupilumab |
| Target | IL4R |
| Heavy Chain | EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS |
| Light Chain | DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK |
| 100% seqID Fv Structure | 6wgb%3AAB%3ACD%2F6wgj%3AAB%3ACD%3AEF%2F6wgk%3AAB%3ACD%3AEF%3AGH%2F6wgl%3AAB%2F6wg8%3AAB [Fvs: ] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G4 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | VelocImmune Mouse |
| INN Year Proposed | 2012 |
| INN Year Recommended | 2013 |
| Companies Involved | Aimmune Therapeutics%3BRegeneron Pharmaceuticals%3BSanofi |
| Conditions Approved | Asthma%3BAtopic dermatitis |
| Conditions Active | Nasal polyps%3BChronic obstructive pulmonary disease%3BEosinophilic oesophagitis%3BGrass pollen hypersensitivity%3BPeanut hypersensitivity%3BUrticaria%3BAllergic asthma |
| Conditions Discontinued | na |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
